文献速递其他结缔组织病

系统性硬化症患者间质性肺疾病的发病率:EUSTAR队列分析

The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133).
PubMed 文献 · Ann Rheum Dis · 2026-01-17

基于EUSTAR队列中5331例基线高分辨率CT无间质性肺病征象的系统性硬化症患者,新发间质性肺病的发病率为3.83例/100人年,且从基线起持续检测到新发间质性肺病达10年;新发间质性肺病的风险因素包括纽约心脏病协会心功能分级≥2级、肌无力、高炎症标志物及系统性硬化症特异性自身抗体,而与疾病病程无关。与基线时已存在间质性肺病者相比,新发间质性肺病患者疾病进展风险较低,但仍与死亡率升高相关,其死亡风险约为无间质性肺病者的两倍。

要点

  • 基线高分辨率CT阴性的系统性硬化症患者新发间质性肺病发病率为3.83例/100人年。
  • 新发间质性肺病风险因素包括纽约心脏病协会心功能分级≥2级、肌无力、高炎症标志物及系统性硬化症特异性自身抗体,与疾病病程无关。
  • 新发间质性肺病仍与死亡率升高相关,死亡风险约为无间质性肺病者的两倍。

核心结论

  • 基线高分辨率CT无间质性肺病征象的系统性硬化症患者仍存在持续的新发间质性肺病风险,且新发间质性肺病与死亡率升高相关。
  • 建议对基线高分辨率CT阴性的系统性硬化症患者进行定期筛查,尤其当存在新发间质性肺病高危特征时。

研究设计与样本

  • EUSTAR队列分析,纳入基线高分辨率CT无间质性肺病征象且至少1次随访具有高分辨率CT数据的系统性硬化症患者,共5331例。
  • 新发间质性肺病发病率按每100人年计算;新发间质性肺病预测因素及间质性肺病进展和死亡风险因素依据文献和专家意见选择,分别采用广义逻辑估计方程和Cox回归模型检验。

主要发现

  • 5331例基线高分辨率CT阴性的系统性硬化症患者中,新发间质性肺病发病率为3.83例/100人年。
  • 从基线起持续检测到新发间质性肺病达10年。
  • 新发间质性肺病风险因素包括纽约心脏病协会心功能分级≥2级、肌无力、高炎症标志物及系统性硬化症特异性自身抗体,但疾病病程不是风险因素。
  • 与基线时已存在间质性肺病者相比,新发间质性肺病进展风险较低,但仍与死亡率升高相关,死亡风险约为无间质性肺病者的两倍。

关键数值与推荐

  • 新发间质性肺病发病率:3.83例/100人年(5331例基线高分辨率CT阴性的系统性硬化症患者)。
  • 新发间质性肺病风险因素:纽约心脏病协会心功能分级≥2级、肌无力、高炎症标志物、系统性硬化症特异性自身抗体;疾病病程不是风险因素。
  • 新发间质性肺病者死亡风险约为无间质性肺病者的两倍。

临床怎么用

  • 对基线高分辨率CT阴性的系统性硬化症患者应考虑定期筛查间质性肺病,尤其当存在新发间质性肺病高危特征时。
  • 评估新发间质性肺病风险时可关注纽约心脏病协会心功能分级≥2级、肌无力、高炎症标志物及系统性硬化症特异性自身抗体,而非仅依据疾病病程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Interstitial lung disease (ILD) carries significant morbidity and mortality risk in systemic sclerosis (SSc). We aimed to estimate the incidence of new-onset SSc-ILD and the associated risk factors, as well as its impact on the prognosis. METHODS: Patients classified as having SSc, with the absence of ILD signs on high-resolution computed tomography (HRCT) at baseline and having at least 1 follow-up visit with available HRCT data, were selected. SSc-ILD incidence was calculated as a rate per 100 person-years. Predictors of new-onset ILD and risk factors for ILD progression and mortality were chosen according to the literature and expert opinion. Risk factors for new-onset ILD, as well as its prognostic impact on ILD progression and mortality, were tested by generalised logistic estimating equation and Cox regression models, respectively. RESULTS: Among 5331 patients with SSc with negative baseline HRCT, the incidence of new-onset ILD was 3.83 cases per 100 person-years. Notably, there was a continuous detection of new ILD onset up to 10 years from baseline. Risk factors for new-onset ILD included New York Heart Association stage ≥2, muscle weakness, high inflammatory markers, and SSc-specific autoantibodies, but not disease duration. Despite a lower risk of ILD progression compared with prevalent ILD diagnosed at baseline, incident ILD still carried an increased risk for mortality, which was almost double when compared with ILD-negative cases. CONCLUSIONS: Patients with SSc should be considered for regular screening following a negative baseline HRCT, in particular when carrying high-risk features for new ILD onset, given its incidence and prognostic implications.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Petelytska L, Tofani L, Velauthapillai A, et al. The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133). Ann Rheum Dis. 2026. PMID: 41549016. doi:10.1016/j.ard.2025.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。